Format
Items per page
Sort by

Send to:

Choose Destination

Results: 8

1.

Pediatric invasive pneumococcal disease in the United States in the era of pneumococcal conjugate vaccines.

Tan TQ.

Clin Microbiol Rev. 2012 Jul;25(3):409-19. doi: 10.1128/CMR.00018-12. Review.

2.

Licensure of 13-valent pneumococcal conjugate vaccine for adults aged 50 years and older.

Centers for Disease Control and Prevention (CDC).

MMWR Morb Mortal Wkly Rep. 2012 Jun 1;61(21):394-5.

3.

Impact of 13-valent pneumococcal conjugate vaccine on pneumococcal nasopharyngeal carriage in children with acute otitis media.

Cohen R, Levy C, Bingen E, Koskas M, Nave I, Varon E.

Pediatr Infect Dis J. 2012 Mar;31(3):297-301. doi: 10.1097/INF.0b013e318247ef84.

PMID:
22330166
4.

Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: comparing estimates for 7-valent, 10-valent, and 13-valent vaccines.

Tyo KR, Rosen MM, Zeng W, Yap M, Pwee KH, Ang LW, Shepard DS.

Vaccine. 2011 Sep 2;29(38):6686-94. doi: 10.1016/j.vaccine.2011.06.091. Epub 2011 Jul 13.

PMID:
21745516
6.
7.

Invasive pneumococcal disease in young children before licensure of 13-valent pneumococcal conjugate vaccine - United States, 2007.

Centers for Disease Control and Prevention (CDC).

MMWR Morb Mortal Wkly Rep. 2010 Mar 12;59(9):253-7.

8.

Current knowledge regarding the investigational 13-valent pneumococcal conjugate vaccine.

Dinleyici EC, Yargic ZA.

Expert Rev Vaccines. 2009 Aug;8(8):977-86. doi: 10.1586/erv.09.68. Review.

PMID:
19627181
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk